Ardat

New model systems

Developing improved and sustainable model systems for predicting product safety

Therapy improvement

Enhancing gene therapy vectors for better immune evasion and stability

Regulatory engagement

Establishing a comprehensive database on safety and efficacy of advanced therapies

About ARDAT

A new consortium of 34 international partners from academia, industry, and small/medium enterprises with the aim to develop and provide tools to advance our knowledge in the field of viral gene/cell therapy to accelerate the development of new treatments for rare diseases

0
international partners
0
countries
0
months interval
What we do

Project structure

ARDAT

Accelerating Research & Development for Advanced Therapies

Work package 1

Project management to specify processes and principles

Work package 2

Standardized models for predicting product immunogenicity

Work package 3

Understanding of gene/cell therapy drug metabolism

Work package 4​

Clinical factors around pre-existing immunity​

What we do

Project structure

Work package 1

Project management to specify processes and principles

Work package 2

Standardized models for predicting product immunogenicity

Work package 3

Understanding of gene/cell therapy drug metabolism

Work package 4​

Clinical factors around pre-existing immunity​

Work package 5

Engagement with regulators and database development

Overview of the work plan

Principal project objectives

Pre-clinical studies

Developing standardized models for predicting immunogenicity

Vector enhancement

Understanding gene/cell therapy drug molecular stability and metabolism

Clinical research

Investigating clinical factors around pre-existing immunity

Data Processing & Analysis

Establish a comprehensive and sustainable database on safety and efficacy of advanced therapies